Evidence map›Paper›PMID 34337181›Full record

ArticleHeliyon2021

Determination of O

Yahdiana Harahap, Athalia Theda Tanujaya, Farhan Nurahman, Aurelia Maria Vianney, Denni Joko Purwanto

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yahdiana HarahapBioavailability/Bioequivalence Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia.
Athalia Theda TanujayaBioavailability/Bioequivalence Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia.
Farhan NurahmanBioavailability/Bioequivalence Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia.
Aurelia Maria VianneyBioavailability/Bioequivalence Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia.
Denni Joko PurwantoDharmais Cancer Hospital, West Jakarta, 11420, Jakarta, Indonesia.
University of Indonesia · IDDharmais Cancer Hospital · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclophosphamide is a nitrogen mustard class of drugs that are often used in cancer chemotherapy. However, the use of Cyclophosphamide in high doses over a long period has been shown to increase the risk of developing secondary cancer. This can be indicated by the formation of mutagenic DNA adducts, such as O

Indexed as

CyclophosphamideDried blood spot (DBS)O6-MethylguanineSecondary cancerUPLC-MS/MS

Identifiers

PMID34337181
PMCPMC8313492
OpenAlexW3181932133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.